Drugs / Efgartigimod PH20
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT04777734 | — | polyneuropathy, inflammatory demyelinating, chronic | argenx | Available | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07673627 Background | Jun 2026 → Oct 2027 expected | AChR+ myasthenia gravis, generalized myasthenia gravis | argenx | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Efgartigimod PH20 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04777734 ↗ |
| Route | Subcutaneous | “Subcutaneous administration of Efgartigimod PH20 (via vial or prefilled syringe)” NCT04777734 ↗ |